The Role of Oral Contraceptives in the Treatment of Hyperandrogenic Disorders

The American Journal of Medicine

Volumn 98, Issue 1 SUPPL. 1, 1995, Pages

  Burkman Jr , Ronald T ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ANDROSTENEDIONE; DESOGESTREL; ESTROGEN; ETHINYLESTRADIOL; FOLLITROPIN; GESTAGEN; LEVONORGESTREL; LUTEINIZING HORMONE; MESTRANOL; NANDROLONE DERIVATIVE; NORETHISTERONE ACETATE; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; SPIRONOLACTONE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

ACNE; ANOVULATION; CONFERENCE PAPER; DIABETES MELLITUS; DOSE RESPONSE; DRUG FORMULATION; DRUG MECHANISM; DYSLIPIDEMIA; ENDOMETRIUM HYPERPLASIA; FEMALE; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERTENSION; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL;

ADRENAL GLANDS; ANDROGENS; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HUMAN; HYPERANDROGENISM; OXIDOREDUCTASES; RECEPTORS, ANDROGEN;

EID: 0028921507     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(99)80071-0     Document Type: Article

References (26)

1. The treatment of hyperandrogenism with oral contraceptives
2. Contraceptive choices for women with endocrine complications
3. Idiopathic hirsutism; an ovarian abnormality
4. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome
5. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones
6. Lipid and Carbohydrate Effects of a New Triphasic Oral Contraceptive Containing Norgestimate
7. Evaluation of a new generation of oral contraceptives
8. Effect of low-dose oral contraceptive on gonadotropins, androgens, and sex hormone binding globulin in nonhirsute women
9. Dynamics of suppression and recovery of plasma FSH, LH, androstenedione and testosterone in polycystic ovarian disease
10. Hirsutism: metabolic effects of two commonly used oral contraceptives and spironolactone
11. The treatment of hirsutism with a combination of desogestrel and ethinyl oestradiol
12. Comparative Contraceptive Efficacy and Mechanism of Action of the Norgestimate-Containing Triphasic Oral Contraceptive
13. Plasma testosterone binding globulin and indexes of the concen-tration of unbound plasma androgens in normal and hirsute subjects
14. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone
15. Normalization of testosterone levels using a low estrogen-containing oral contraceptive in women with polycystic ovary syn-drome
16. Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives
17. Differential studies on the mechanism of serum androgen and androgen-binding abnormalities in hirsutism
18. SEX HORMONE BINDING GLOBULIN CAPACITY AS AN INDEX OF OESTROGENICITY OR ANDROGENICITY IN WOMEN ON ORAL CONTRACEPTIVE STEROIDS
19. A Comparison Study of Lipid and Androgen Metabolism with Triphasic Oral Contraceptive Formulations Containing Norgestimate or Levonorgestrel
20. The prevalence and significance of elevated dehydroepiandrosterone sulfate levels in anovulatory women
21. Selectivity and Minimal Androgenicity of Norgestimate in Monophasic and Triphasic Oral Contraceptives
22. Adrenal function in hirsutism. II. Effect of an oral contraceptive
23. Fertility following discontinuation of different methods of fertility control
24. Modern trends in contraception
25. Effects of a low-dose desogestrel-ethinylestradiol combination on hirsutism, androgens and sex hormone binding globulin in women with a polycystic ovary syndrome
26. Clinical tolerance of a low-dose norgestimate-containing combination oral contraceptive (Cilest) in a West German multicenter study (Heidelberg Multicenter Oral Contraceptive Study)